En analyse af virkningen på NSCLCs histologi for behandlingens virkning på samlet overlevelse var til fordel for ALIMTA versus docetaxel bortset fra cancerformer hovedsageligt bestående af pladeepitelceller (n=399; 9, 3 mod 8, 0 måneder, justeret HR= 0, 78; 95% CI= 0, 61- 1, 00, p= 0, 047) og til fordel for docetaxel for carcinom af pladeepitelceller (n= 172; 6, 2 versus 7, 4 måneder, justeret HR 1, 56; 95% CI= 1, 08- 2, 26, p= 0, 0018).
An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of ALIMTA versus docetaxel for other than predominantly squamous histologies (n=399, 9.3 versus 8.0 months, adjusted HR = 0.78; 95% CI =0 .61-1.00, p =0.047) and was in favour of docetaxel for squamous cell carcinoma histology (n=172, 6.2 versus 7.4 months, adjusted HR = 1.56; 95% CI =1.08-2.26, p =0.018).